StockData
Pacific Biosciences of California, Inc. logo

Pacific Biosciences of California, Inc. (PACB) stock

PACBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$1.96−0.01 (-0.51%)

Close on Nov 13, 2026Market cap $609.23MP/E –Yield 0.00%

Earnings

Pacific Biosciences of California's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$40.60M
Non-GAAP net loss per share, Q3 FY2026
$0.11
-$0.12 a year earlier
Latest guidance
Issued
Nov 4, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Pacific Biosciences of California's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$40.60M–$0.12$0.11Release
Q2 FY2026ended Jun 30, 2026Aug 5, 2026after the close$39.00M-2.0%-$0.14-$0.14Release
Q1 FY2026ended Mar 31, 2026May 7, 2026after the close$37.20M0.0%-$0.03-$0.12Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026after the close$44.60M+13.8%-$0.13-$0.12Release
Q3 FY2025ended Sep 30, 2025Nov 5, 2025after the close––-$0.13-$0.12Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025after the close$39.80M+10.6%-$0.14-$0.13Release
Q1 FY2025ended Mar 31, 2025May 8, 2025after the close$37.20M-4.1%$1.44$0.15Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025after the close$39.20M-32.9%-$0.49-$0.20Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close$40.00M-28.2%-$0.22-$0.17Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close$36.00M-24.4%$0.64$0.20Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close$38.80M-0.3%$0.29$0.26Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Pacific Biosciences of California's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueFY2026$155.00M – $160.00M–NewNov 4, 2026
revenueFY2026$155.00M – $165.00M$165.00M – $175.00MLoweredAug 5, 2026

Guidance history

Every forecast Pacific Biosciences of California put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 4, 2026revenueFY2026$155.00M – $160.00MNew
Aug 5, 2026revenueFY2026$155.00M – $165.00MLowered
May 7, 2026revenueFY2026$165.00M – $175.00MNew
Apr 9, 2025non-GAAP gross marginFY202535% – 40%New
Apr 9, 2025revenueFY2025$155.00M – $170.00MNew
Oct 30, 2023GAAP gross profit %FY202332% – 34%New
Oct 30, 2023Non-GAAP gross profit %FY202332% – 34%New
Oct 30, 2023GAAP total operating expenseFY2023$391.20M – $394.73MNew
Aug 3, 2022revenueFY2022$138.00M – $145.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Pacific Biosciences of California filed with the SEC as exhibits to Form 8-K or 6-K

  1. PacBio Announces Third Quarter 2026 Financial Results
    Results
  2. PacBio Announces Second Quarter 2026 Financial Results
    Results
  3. PacBio Appoints Mark Van Oene as President and Chief Executive Officer
    Results
  4. PacBio Announces First Quarter 2026 Financial Results
    Results
  5. PacBio Announces the Appointment of Chris Gibson to the Board of Directors
    Update
  6. PacBio Announces Fourth Quarter and Full Year 2025 Financial Results
    Results
  7. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
    Update
  8. Completes Sale of Short-Read Sequencing Assets
    Update
  9. PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
    Results
  10. PacBio Announces Third Quarter 2025 Financial Results
    Results
  11. PacBio Announces Second Quarter 2025 Financial Results
    Results
  12. PacBio Announces First Quarter 2025 Financial Results
    Results
  13. PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million
    Results
  14. Jim Gibson to join PacBio as Chief Financial Officer
    Update
  15. PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
    Results

See a number that looks wrong?